

DOCKET NO.: UNGR-1598

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Evan C. Unger, et al.

Serial No.: 09/699,679

Group Art Unit: 1619

Filed: **October 30, 2000**

Examiner: **Michael A. Willis**

For: **NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND
THERAPEUTIC USE**

I, **S. Maurice Valla**, Registration No. 43,966 certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

On December 18, 2001


S. Maurice Valla, Reg. No. 43,966

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

RESPONSE TO RESTRICTION REQUIREMENT

A restriction requirement dated November 27, 2001 has been received for the above-referenced application. The Examiner has required an election of one of four groups of claims, identified as:

- | | |
|-----------|-------------------------------|
| Group I | Claims 1-35; |
| Group II | Claims 36 to 38 and 41 to 50; |
| Group III | Claims 39 to 40; and |
| Group IV | Claims 51 to 53. |

TECH CENTER 1600/2900

PATENT
JAN 24 2002
RECEIVED

#11
JRP
1/26/02

It is stated in the Office Action that the various groups are directed to distinct inventions. Applicant hereby elects for prosecution the claims of Group I (Claims 1 to 35). Applicant expressly reserves the right to file one or more divisional applications directed to the subject matter originally presented in the non-elected claims.

The Examiner has also required an election of a single species. It is Applicant's understanding that this election is being made to aid the Examiner in conducting a search and examination of the claimed subject matter, and is not to be construed as limiting the scope of Applicant's claims. It is also Applicant's understanding that if the elected subject matter is found to be allowable over the prior art, the search and examination will be expanded to cover other species, until it includes the full scope of the generic claims included in the elected group.

Applicant hereby elects a species of the compound defined by Claim 1, wherein:

X¹ is a direct bond; ✓

X² is -N(R⁸)-C(=X³);

X³ is O;

R¹ is acyl of 18 carbons;

R² is H;

R³ is a direct bond;

R⁴ is acyl of 18 carbons;

R⁵ is acetyl;

R⁶ and R⁷ are each direct bonds; ✓

R⁸ is acetyl;

P is PEG-3400; and ✓


T comprises a peptide having the sequence CRGDC, wherein the two cysteines are linked together via a disulfide linkage.

With regard to the request that Applicants elect a single species of vesicles for claims 17 to 35, Applicants elect a vesicle composition that comprises a liposome that comprises dipalmitoylphosphatidylethanolamine and is filled with perfluorobutane gas, and further comprises urokinase.

CONCLUSION

Applicants believe that the foregoing constitutes a complete and full response to the Office Action of record. An early and favorable consideration of the present application is respectfully requested.

Respectfully submitted,



S. Maurice Valla

Registration No. 43,966

Date: **December 18, 2001**

**WOODCOCK WASHBURN KURTZ
MACKIEWICZ & NORRIS LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
(215) 568-3100**